Phillip A. Sharp - Feb 29, 2024 Form 4 Insider Report for ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Role
Director
Signature
By: Stephen Hall, Attorney-in-Fact For: Phillip A. Sharp
Stock symbol
ALNY
Transactions as of
Feb 29, 2024
Transactions value $
-$2,762,571
Form type
4
Date filed
3/1/2024, 04:12 PM
Previous filing
May 24, 2023
Next filing
May 20, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALNY Common Stock Options Exercise $1.78M +30K $59.25 30K Feb 29, 2024 Direct F1
transaction ALNY Common Stock Sale -$1.96M -13K -43.35% $150.60 17K Feb 29, 2024 Direct F1, F2
transaction ALNY Common Stock Sale -$2.05M -13.6K -79.77% $151.43 3.44K Feb 29, 2024 Direct F1, F3
transaction ALNY Common Stock Sale -$139K -915 -26.61% $152.40 2.52K Feb 29, 2024 Direct F1, F4
transaction ALNY Common Stock Sale -$293K -1.91K -75.54% $153.62 617 Feb 29, 2024 Direct F1, F5
transaction ALNY Common Stock Sale -$15.6K -101 -16.37% $154.07 516 Feb 29, 2024 Direct F1, F6
transaction ALNY Common Stock Sale -$80.8K -516 -100% $156.54 0 Feb 29, 2024 Direct F1, F7
holding ALNY Common Stock 267K Feb 29, 2024 by Trust F8

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALNY Stock Option (right to buy) Options Exercise $0 -30K -100% $0.00* 0 Feb 29, 2024 Common Stock 30K $59.25 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2023. The 30,000 options exercised and sold by the reporting person were due to expire on June 4, 2024.
F2 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $150.00 to $151.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $151.01 to $151.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $152.02 to $152.91. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $153.04 to $154.03. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F6 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $154.06 to $154.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F7 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $156.15 to $156.98. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F8 Includes shares held by the Phillip A. Sharp Revocable Trust, of which the reporting person and his spouse are co-trustees. Also includes shares held in trust for the benefit of the reporting persons children, of which the reporting persons children and spouse are the trustees.